Navigation Links
Vaccine approach extends life of metastatic prostate cancer patients
Date:1/25/2010

BOSTONIn a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations. The findings will be published by the Journal of Clinical Oncology on its Web site and later in a print edition.

The randomized phase II study involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of prostate specific antigen (PSA) a protein on the surface of prostate cells that is abnormal in many prostate cancers and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells. The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine, produced by BN ImmunoTherapeutics, Inc., of Mountain View, Cal., and 40 received a placebo.

At the three-year point after the study, 30 percent of the PROSTVAC-VF patients were alive, versus 17 percent of the control group. The median survival of the vaccine group was 24.5 months, compared to 16 months for the control group, an 8.5-month increase. Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea.

"Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach," says principal investigator and lead author Philip Kantoff, MD, of Dana-Farber, who helped design the trial. Investigators are planning a phase III trial that will enroll about 600 patients to further evaluate the vaccine's effectiveness.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. H1N1 Vaccines Still Available in North Dallas
2. Concentra Supports National Influenza Vaccination Week, Offers H1N1 Vaccines
3. Lung Infection Up in Wake of Kids Pneumonia Vaccine
4. As Swine Flu Ebbs, Officials Stress Importance of Vaccine
5. Johns Hopkins researchers say vaccine appears to mop up leukemia cells Gleevec leaves behind
6. Efficacy of flu vaccine drastically reduced for RA patients treated with rituximab
7. Immune responses to tetanus vaccine unchanged for RA patients on rituximab
8. CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States
9. More Than 4 Million Doses of H1N1 Vaccine Allocated to Pennsylvania Since Start of Vaccination Effort
10. Nearly 5 Million Doses of Nasal Swine Flu Vaccine Recalled
11. Department of Health to Offer H1N1 Vaccine Clinics for All Pennsylvanians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump ... preparing for how his administration could impact the employee benefits industry. James Slotnick, ... are most likely to make it through Congress. His discussion will focus on ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
Breaking Medicine Technology: